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Adverse Interactions of Drugs in Critical Care Patients 
Barbara Zarowitz, Pharm D,* William Conway, MD,+ and John Popovich, Jr, MDt 
Adverse drug reactions are common and potentially 
lethal complications of modern medical treatment (1,2). 
According to a study by the Boston Collaborative Drug 
Surveillance Program (BCDSP), an estimated 29,000 drug-
related deaths occur each year, and hospital patients 
account for 29% of them (2). In another study, the 
BCDSP monitored 9,900 patients with 83,200 drug ex-
posures and found 3,600 reported adverse reactions (1). 
In 234 instances (6.5%), the adverse reactions were 
attributed to drug interactions. 
Among hospital patients, those in critical care units are 
the most likely to have an adverse drug reaction. Of ten, 
these patients have mult iple organ system failure or 
senescent organ dysfunction and require mechanical 
ventilation or other aggressive pulmonary intervention. 
Organ dysfunction affects drug metabolism and alters 
normal el imination characteristics (3). Because they 
may need mechanical vent i lat ion w i th tracheal in-
tubation and often have central nervous system dys-
funct ion, they are unable to verbalize early symptoms of 
drug toxicity. Under these circumstances, a previous 
history of drug allergy or adverse drug effects is often 
diff icult to elicit, especially if family members or pre-
vious records are not available. 
Because critically ill patients usually require combina-
tions of medications for the treatment of complicated 
medical disorders, prescribing for them is exceedingly 
complex. Sophisticated, mult iple drug regimens are 
often required, both to treat primary diseases and to 
prevent complications of critical illness. Consequently, 
the number of medications such patients must be given 
increases the l ikel ihood of adverse drug interactions. In 
fact, a logarithmic relationship between the number of 
errors and the number of prescriptions per patient has 
been demonstrated (4). 
It is vital that the staff of critical care units be aware of 
reported drug interactions in order to reduce the poten-
tial hazards of mult iple drug therapy. Guidelines fotl 
ident i fy ing potent ia l ly impor tant drug in teract ion^ 
include: 
1. understanding the sites and mechanisms of drug 
actions and the drugs that predictably interact at 
these sites; 
2. understanding the pathophysiology of the patientl l 
diseases and the pharmacology of the drugs being 
used to treat them; 
3. using as few drugs as possible per patient regimeni 
to minimize the potential for interactions; and 
4. recognizing that differences between individud 
patients in their reactions to drugs can produce sub-
stantial variabil ity in the pharmacological conse-
quences of the interaction. 
The Table on the fol lowing pages details 40 of the most 
frequently occurring drug interactions in critically ill 
patients. The drugs are listed in alphabetical order. This 
is by no means a comprehensive list of all relevant drug 
interactions; compendious lists are available elsewhere 
(5-8). Our purpose is to provide examples of drug inter-
actions whose consequences are frequent and severe 
enough to warrant the attention of practitioners in the 
area. 
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Table 
Adverse Drug Interactions in Critical Care Patients 
Effect Mechanism Comments/Recommendat ions 
Bumetanide 
Ethacrynic acid 
Furosemide 
Neuromuscular 
b locking agents 
Penicillins 
see Theophyl l ine 
Digitalis 
Neuromuscular 
b locking agents 
Oral d igoxin 
Salicylates 
Quin id ine 
Antacids 
Heparin 
Warfar in 
Beta blockers 
Chloramphenicol 
Cort icosteroids 
Qu in id ine 
Rifampin 
Increased risk of 
ototoxici ty 
Increased risk of 
ototoxici ty 
Increased risk of 
ototoxici ty 
Neuromuscular 
blockade 
Relative 
inactivation of 
both antibiotics 
Increased risk of 
digitalis toxicity 
Increased curar i form 
effect 
Decreased digoxin 
effect 
Decreased 
salicylate levels 
Increased quin id ine 
levels/effect 
Decreased 
salicylate levels 
Increased risk of 
bleeding 
Increased risk of 
bleeding 
Decreased beta 
blockade 
Increased 
barbiturate effect 
Decreased steroid 
effect 
Decreased 
quin id ine effect 
Decreased 
barbiturate effect 
Addit ive 
Addit ive 
Addit ive 
Addit ive 
Formation of 
inactive 
conjugate 
Amphoter ic in-
induced renal 
potassium wasting 
Amphoter ic in-
induced renal 
potassium wasting 
Decreased 
absorption 
Increased renal 
clearance 
Decreased renal 
clearance 
Increased renal 
clearance 
Inhib i t ion of 
platelet funct ion 
Addit ive 
Induct ion of 
microsomal enzymes 
Inhibi t ion of 
microsomal enzymes 
Induct ion of 
microsomal enzymes 
Induct ion of 
microsomal enzymes 
Induct ion of 
microsomal enzymes 
Transient or permanent 
hearing loss 
Increased risk wi th 
IV administrat ion and 
preexisting renal failure 
Reversible wi th calcium 
Separate administrat ion 
times by 1-2 hrs 
Mon i to r serum potassium 
closely 
Replace as needed 
Separate administrat ion 
times 
Increase salicylate dose 
as required 
Mon i to r quin id ine b lood 
level; decrease qu in id ine 
dose as required 
Increase salicylate dose 
as required 
Avoid combinat ion 
&3 gm ASA/day may enhance 
hypoprothrombinemia 
ss3 gm ASA/day inhibits 
platelet aggregation; A V O I D 
Increase beta blocker dose 
as required 
Significant, moni tor 
barbiturate levels 
Increase steroid dose as 
required 
Increase qu in id ine dose as 
required 
Increase barbiturate dose 
as required 
Reference 
10-12 
13,14 
15-17 
18 
13,14,18,19 
20 
21 
22 
21 
23 
24 
25,26 
27 
28 
29,30 
49 
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Table 
Adverse Drug Interactions in Critical Care Patients 
Drug Drug Effect Mechanism Comments/Recommendat ions Reference Drug 
Barbiturates 
(cont) Valproic acid Increased 
barbiturate effect 
Inhibi t ion of 
microsomal enzymes 
Mon i to r barbiturate levels Cimetidine 
Benzodiazepines Cimet id ine Increased benzo-
diazepine effect 
(diazepam/chlor-
diazepoxide) 
Inhibi t ion of 
microsomal enzymes 
Substitute lorazepam or 
oxazepam 
32-35 
Neuromuscular 
b locking agents 
Increased curar i form 
effect (gallamine, 
tubocurar ine, 
pancuronium) 
Limits release of 
acetyl chol ine; 
additive 
Not observed w i th 
depolarizing agents 
(decamethonium, 
succinlycholine) 
36 
Beta blockers Anesthetics, 
general 
Hypotension Potentially 
additive 
Moni tor b lood pressure 
closely 
37 
Barbiturates Decreased beta 
blockade 
Induct ion of 
microsomal enzymes 
Increase beta blocker dose 
as required 
24 
Cimet id ine Increased beta 
blocker levels/ 
effect 
Decreased hepatic 
clearance (mean 
27%) 
Observe closely 38 
Lidocaine Increased l idocaine 
effect 
Decreased hepatic 
clearance of 
l idocaine 
May require l idocaine 
dosage reduct ion 
39 
Neuromuscular 
b lock ing agents 
Prolonged neuro-
muscular blockade 
Potentially 
synergistic 
Significant w i th large 
propranolol doses 
(120 mg/day oral) 
7,40 
Theophyl l ine Increased 
theophyl l ine levels/ 
effect 
Decreased 
theophyl l ine 
clearance (mean 40%) 
Mon i to r theophyl l ine levels; 
decrease dose as required 
41 Corticosterc 
Verapamil Increased negative 
chronotropic and 
inotropic effects 
Addit ive May be significant in 
patients wi th impaired left 
ventricular performance 
and/or angina 
42,43 
Calcium channel 
blockers 
Beta blockers Increased negative 
inotropic and 
chronotrop ic 
effects 
Addit ive May be significant in 
patients wi th impaired left 
ventricular performance 
and/or angina 
42,43 
Curariform 
drugs 
Carbenici l l in 
Digoxin 
see Penicillins 
Increased digoxin 
levels 
Decreased renal 
and nonrenal 
clearance 
May require digoxin dosage 
reduct ion 
44 Dextran 
Dialtiazem 
Chloramphenicol Barbiturates Increased 
barbiturate effect/ 
toxicity 
Inhibi t ion of 
microsomal enzymes 
Mon i to r barbiturate 
levels and decrease 
dose as required 
25,26 Digoxin 
Phenytoin Increased 
phenytoin effect/ 
toxicity 
Inhibi t ion of 
microsomal enzymes 
Mon i to r phenytoin 
levels and decrease 
dose as required 
25,45 
Chlordiazepoxide see Benzodiazep nes 
SO 
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Table 
Drug 
Beta blockers 
Adverse Drug Interactions in Critical Care Patients 
Effect Mechanism Comments/Recommendat ions 
Increased beta 
blockade 
Decreased hepatic Observe closely 
clearance 
Reference 
38 
Benzodiazepines Increased 
benzodiazepine 
levels/effect 
Inhib i t ion of Substitute lorazepam or 
microsomal enzymes oxazepam 
32-35 
Lidocaine 
Narcotic 
analgesics 
Phenytoin 
Increased lidocaine 
levels/effect 
Increased narcotic 
effect, respiratory 
depression 
Increased phenytoin 
effect 
Increase in 
hematological 
abnormalit ies 
Decreased 
lidocaine's 
hepatic clearance 
May require l idocaine dosage 
reduct ion 
Inhibi t ion of Mon i to r patients closely 
microsomal enzymes 
Inhib i t ion of 
microsomal enzymes 
Possible additive 
Mon i to r phenytoin levels 
Mon i to r hematologic values 
32,46 
47 
48,49 
34 
Corticosteroids 
Theophyl l ine 
Warfarin 
Barbiturates 
Increased 
theophyl l ine levels/ 
effect 
Enhanced 
hypoprothrobinemic 
effect of warfarin 
Decreased 
cort icosteroid 
effect 
Inhibi t ion of 
microsomal enzymes 
(mean clearance 
decrease of 40%) 
Inhibi t ion of 
microsomal enzymes 
Induct ion of 
microsomal enzymes 
Mon i to r theophyl l ine levels; 50,51 
effect occurs w i th in 48 hrs 
Mon i to r p ro th rombin t ime ; 34,52 
signif icant; decrease 
warfarin dose as required 
Increase steroid dose as 27 
required 
Phenytoin Decreased 
cort icosteroid 
effect 
Induct ion of Increase cort icosteroid 
microsomal enzymes dose as required 
53-55 
Rifampin 
Curariform 
drugs 
Dextran 
Dialtiazem 
Digoxin 
Decreased 
cort icosteroid 
effect 
Induct ion of Increase cort icosteroid 
microsomal enzymes dose as required 
56 
see Neuromuscular 
b locking agents 
Heparin 
see Calcium 
channel blockers 
Amphoter ic in B 
Antacids 
Antibiot ics (oral) 
Increased bleeding 
Increased digoxin 
toxicity 
Decreased digoxin 
levels/effect 
Increased digoxin 
effect 
Synergistic 
anticoagulation 
Hypokalemia 
Decreased oral 
digoxin absorpt ion 
Inactivation of gut 
flora by antibiotic 
Avoid combinat ion 
Mon i to r serum potassium and 
replace as required 
Separate administrat ion 
times 
May occur in 10-20% of 
populat ion 
57 
7,18 
20 
51 
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Table 
Adverse Drug Interactions in Critical Care Patients 
Drug Drug Effect Mechanism Comments/Recommendations Reference i Drug 
Digoxin 
(cont) 
Calcium channel 
blockers 
Cholestyramine 
Increased digoxin 
levels/effect 
Decreased digoxin 
levels/effect 
Reduced renal and 
nonrenal clearance 
Reduced oral 
absorption 
Monitor patient closely; 
reduce digoxin dose as 
required 
Separate administration 
times by 4-6 hrs 
44 
59 
Narcotic 
analgesics (co 
Neuromuscul 
blocking ager 
Diuretics Increased digoxin 
toxicity 
Hypokalemia Monitor serum potassium and 
replace as required 
60 
Kaolin pectin Decreased digoxin 
levels/effect 
Reduced oral 
absorption 
Separate administration 
times by 4-6 hrs 
20 
Procainamide 
Quinidine 
Increased digoxin 
levels/effect 
Altered excretion 
and tissue binding 
Monitor closely; may require 
30-50% reduction in digoxin 
dosage 
61-63 
Vasodilators Decreased digoxin 
levels/effect 
Increased renal 
clearance 
(mean 50%) 
May require digoxin dosage 
increase; observed with 
hydralazine, nitroprusside 
64 
Diuretics Aminoglycosides Increased risk of 
ototoxicity 
Additive Increased risk with IV 
administration and 
preexisting renal disease 
10,11 
Digoxin Increased digoxin 
toxicity 
Hypokalemia Monitor serium potassium and 
replace as required 
60 
Erythromycin Digoxin 
Theophylline 
Increased digoxin 
effect 
Increased 
theophylline 
levels/effect 
Inactivation of 
gut flora by 
erythromycin 
Inhibition of 
theophylline 
clearance 
(mean 25%) 
May occur in 10-20% of 
population 
Occurs at 5-7 days; monitor 
theophylline levels and 
reduce dose as required 
58 
65-68 
Nifedipine 
Pancuronium 
bromide 
Penicillins 
Ethacrynic acid see Diuretics Phenytoin 
Furosemide see Diuretics 
Heparin Aspirin Increased risk of 
bleeding 
Inhibition of 
platelet function 
Avoid combination 23 
Dextran Increased risk of 
bleeding 
Synergistic 
anticoagulation 
Avoid combination 57 
Lidocaine Barbiturates Decreased lidocaine 
levels/effect 
Induction of 
microsomal enzymes 
Increase lidocaine infusion 
rate as required 
69 
Beta blockers Increased lidocaine 
levels/effect 
Decreased hepatic 
blood flow and 
clearance 
Reduce lidocaine 
infusion rate as 
required 
39 
Neuromuscular 
blocking agents 
Increased curariform 
effect 
Potentiation Monitor patient closely 19 
Procainamid 
Narcotic 
analgesics 
Beta blockers Central nervous 
system depression 
Unknown Monitor patient closely 70 
Cimetidine Increased narcotic 
effect 
Decreased hepatic 
clearance 
52 
Monitor patient closely 34,47 
Reference Drug Drug 
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Table 
Adverse Drug Interactions in Critical Care Patients 
Effect Mechanism Comments/Recommendat ions Reference 
Narcotic 
analgesics (cont) 
Neuromuscular 
blocking agents 
Nifedipine 
Pancuronium 
bromide 
Penicillins 
Phenytoin 
Procainamide 
Neuromuscular 
b lock ing agents 
Respiratory 
depression 
Aminoglycosides Neuromuscular 
blockade 
Amphoter ic in B 
Cl indamycin 
Diuretics 
Lidocaine 
Narcotic 
analgesics 
Procainamide 
Qu in id ine 
Increased curar i form 
effect 
Neuromuscular 
blockade 
Increased 
curar i form effect 
Increased 
curar i form effect 
Respiratory 
depression 
Increased 
curar i form effect 
Increased 
curar i form effect 
see Calcium 
channel blockers 
see Neuromuscular 
b lock ing agents 
Aminoglycosides 
Chloramphenicol 
Cimet id ine 
Cort icosteroids 
Qu in id ine 
Neuromuscular 
b locking agents 
Decreased b lood 
levels of both drugs 
Increased phenytoin 
levels/toxicity 
Increased phenytoin 
levels/toxicity 
Increase in 
hematological 
abnormalit ies 
Decreased cort ico-
steroid effect 
Decreased quin id ine 
effect 
Increased neuro-
muscular blockade 
Addit ive 
Addit ive 
Amphoter ic in 
induced renal 
potassium wasting 
Addit ive 
Hypokalemia 
Potentiation 
Addit ive 
Addit ive 
Addit ive 
Mon i to r patient closely 
Reversible wi th calcium 
Moni to r serum potassium and 
replace as required 
Mon i to r patient closely 
Mon i to r serum potassium and 
replace as required 
Mon i to r patient closely 
Mon i to r patient closely 
Mon i to r patient closely 
Mon i to r patient closely 
Formation of an 
inactive conjugate 
Inhibi t ion of 
microsomal enzymes 
Inhib i t ion of 
microsomal enzymes 
Possibly additive 
Induct ion of 
microsomal enzymes 
Separate administrat ion 
times by 1-2 hrs 
Mon i to r phenytoin 
levels and decrease 
dose as required 
Mon i to r phenyto in levels 
Mon i to r hematological 
vaiues 
Induct ion of May increase clearance by 
microsomal enzymes 50%; increase dose as 
required 
Addit ive Mon i to r patient closely 
19 
13,14 
13,14,18,19 
13,19 
19 
19 
19 
19 
19,22 
15-17 
25,45 
48,49 
53-55 
2;i 
19,71 
53 
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Drug Drug 
Table 
Adverse Drug Interactions in Critical Care Patients 
Effect Mechanism Comments/Recommendat ions 
Quin id ine 
Succinyl-choline 
Theophyl l ine 
Tubocurarine 
Ticarcill in 
Verapamil 
Antacids 
Barbiturates 
Digoxin 
Neuromuscular 
b lock ing agents 
Phenytoin 
Sodium 
bicarbonate 
Decreased quin id ine 
levels/effect 
Decreased quin id ine 
levels/effect 
Increased digoxin 
levels/effect 
Increased curar i form 
effect 
Decreased quin id ine 
effect 
Increased quin id ine 
levels 
see Neuromuscular b lock ing agents 
A l lopur ino l 
Cimet id ine 
Erythromycin 
Phenobarbitol 
Phenytoin 
Propranolol 
Rifampin 
Increased 
theophyl l ine 
levels/effect 
Increased 
theophyl l ine 
levels/effect 
Increased 
theophyl l ine 
levels/effect 
Decreased 
theophyl l ine 
levels/effect 
Decreased 
theophyl l ine 
levels/effect 
Increased 
theophyl l ine 
levels/effect 
Decreased 
theophyl l ine 
levels/effect 
see Neuromuscular b locking agents 
see Penicillins 
see Calcium channel blockers 
Increased renal 
clearance 
Increase dose as required 
Induct ion of Increase qu in id ine dose as 
microsomal enzymes required 
Altered excretion Mon i to r closely; may require 
and tissue b ind ing 30-50% reduct ion In digoxin 
dosage 
Addit ive Mon i to r patient closely 
Induct ion of May increase clearance by 
microsomal enzymes 50%; increase dose as 
required 
Decreased renal 
clearance 
Decreased 
theophyl l ine 
clearance 
(mean 25%) 
Decreased 
theophyl l ine 
clearance 
(mean 40%) 
Decreased 
theophyl l ine 
clearance 
(mean 25%) 
Induct ion of 
microsomal enzymes 
(mean clearance 
increase of 25%) 
Induct ion of 
microsomal enzyme 
system (mean 
clearance increase 
75%) 
Decreased 
clearance 
(mean 40%) 
Increased 
clearance 
(mean 25%) 
Decrease dose as required 
Occurs wi th a l lopur inol 
doses &600 mg/day; reduce 
theophyl l ine dose as required 
Mon i to r theophyl l ine levels 
and reduce dose; effect 
occurs w i th in 48 hrs 
Occurs at 5-7 days; moni tor 
theophyl l ine levels and 
reduce dose as required 
Observe; increase dose if 
required 
Interaction may result 
in loss of seizure 
control as we l l ; increase 
doses or avoid combinat ion 
Metopro lo l has only a small 
effect on theophyl l ine 
clearance; avoid propranolo l 
May be caused by r i fampin 
inducing hepatic microsomal 
enzymes; mon i to r patient 
Reference 
22 
2'i 
61-63 
19,71 
28 
22 
72 
50,51 
65-68 
73 
74 
75 
76 
9 
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